Abstract
Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Current Enzyme Inhibition
Title:Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Volume: 12 Issue: 2
Author(s): Bijo Mathew, Githa E. Mathew, Jerad Suresh, Gülberk Ucar, Rani Sasidharan, Sockalingam Anbazhagan, Jobin K. Vilapurathu and Venkatesan Jayaprakash
Affiliation:
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Abstract: Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Export Options
About this article
Cite this article as:
Mathew Bijo, Mathew E. Githa, Suresh Jerad, Ucar Gülberk, Sasidharan Rani, Anbazhagan Sockalingam, Vilapurathu K. Jobin and Jayaprakash Venkatesan, Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders, Current Enzyme Inhibition 2016; 12 (2) . https://dx.doi.org/10.2174/1573408012666160402001715
DOI https://dx.doi.org/10.2174/1573408012666160402001715 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell-Selective Mitochondrial Targeting: Progress in Mitochondrial Medicine
Current Drug Delivery Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry Metabotropic Glutamate Receptors as Drug Targets
Current Drug Targets Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Neuroprotective Effects of Lithium in Human Brain? Food for Thought
Current Alzheimer Research Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Critical Role of Computer Simulations in Drug Discovery and Development
Current Topics in Medicinal Chemistry Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry The Overlapping Syndromes of the Pick Complex
Current Alzheimer Research Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Occupational Complexity and Leisure Activities in Cognitive Aging
Current Psychopharmacology Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Differential Retinal Protein Expressions During form Deprivation Myopia in Albino Guinea Pigs
Current Proteomics Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study
Central Nervous System Agents in Medicinal Chemistry